Clinical trial
A Phase II Randomized Trial of Neoadjuvant Chemotherapy or Chemo-Immunotherapy in Patients With Recurrent/Persistent PD-L1 Enriched Squamous Cell Carcinoma of the Head and Neck Undergoing Salvage Surgery (NEOPOLIS)
NCT07195734 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Randomized Trial of Neoadjuvant Chemotherapy or Chemo-Immunotherapy in Patients With Recurrent/Persistent PD-L1 Enriched Squamous Cell Carcinoma of the Head and Neck Undergoing Salvage Surgery (NEOPOLIS)
- Lead sponsor
- National Cancer Institute (NCI)
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- April 24, 2026
- Completion date
- February 1, 2033
- Enrollment
- 180 (estimated)
- Sites
- 113
Conditions
As the registry lists them; a condition with its own page is linked.
clinical stage ii hpv-mediated (p16-positive) oropharyngeal carcinoma ajcc v8, clinical stage iii hpv-mediated (p16-positive) oropharyngeal carcinoma ajcc v8, locally recurrent head and neck squamous cell carcinoma, locally recurrent hypopharyngeal squamous cell carcinoma, locally recurrent laryngeal squamous cell carcinoma, locally recurrent oral cavity squamous cell carcinoma, locally recurrent oropharyngeal squamous cell carcinoma, stage ii laryngeal cancer ajcc v8, stage ii lip and oral cavity cancer ajcc v8, stage ii oropharyngeal (p16-negative) carcinoma ajcc v8, stage iii laryngeal cancer ajcc v8, stage iii lip and oral cavity cancer ajcc v8, stage iii oropharyngeal (p16-negative) carcinoma ajcc v8, stage iva laryngeal cancer ajcc v8, stage iva lip and oral cavity cancer ajcc v8, stage iva oropharyngeal (p16-negative) carcinoma ajcc v8, stage ivb laryngeal cancer ajcc v8, stage ivb oropharyngeal (p16-negative) carcinoma ajcc v8